Brought to you by 
Aerie Pharmaceuticals raises $41.4mm through its Series B round
08 Mar 2011
Executive Summary
Aerie Pharmaceuticals Inc. (ophthalmic compounds) has raised $41.4mm through its Series B venture round. Clarus Ventures and Sofinnova Ventures led and were joined by Osage University Partners and current shareholders Alta Partners and TPG Biotech. Three other undisclosed investors also participated. The company will use the funds to continue building its glaucoma portfolio and move its lead drug candidate, AR12286, into Phase III within the next nine months.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Aerie Pharmaceuticals raises $41.4mm through its Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice